This article is part of the supplement: Analgesia and sedation in the intensive care unit
The place for short-acting opioids: special emphasis on remifentanil
-
* Corresponding author: Wolfram Wilhelm wolfram.wilhelm@smh-online.de
Critical Care 2008, 12(Suppl 3):S5 doi:10.1186/cc6152
Accesses
- Last 30 days: 139 accesses
- Last 365 days: 1591 accesses
- All time: 10366 accesses
Cited by
BioMed Central: 3 citations
|
Research
Remifentanil discontinuation and subsequent intensive care unit-acquired infection: a cohort study Saad Nseir, Jérémy Hoel, Guillaume Grailles, Aude Soury-Lavergne, Christophe Di Pompeo, Daniel Mathieu, Alain Durocher Critical Care 2009, 13:R60 (21 April 2009) Remifentanil discontinuation is associated with an increased risk of ICU-acquired infection, an observation that reiterates previous reports on the negative effects of opioid withdrawal on the immune system.
|
|
Review
Strategies to optimize analgesia and sedation William D Schweickert, John P Kress Critical Care 2008, 12(Suppl 3):S6 (14 May 2008) |
|
Introduction
Analgesia and sedation in the intensive care unit: an overview of the issues Curtis N Sessler, Wolfram Wilhelm Critical Care 2008, 12(Suppl 3):S1 (14 May 2008) |